Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 17;12(8):ofaf415.
doi: 10.1093/ofid/ofaf415. eCollection 2025 Aug.

Comparison of Infection-Induced SARS-CoV-2 Seroprevalence Across Large-Scale Residual Samples From Blood Donors, Commercial Laboratories, and Health Checkups in Japan, 2023

Asuka Nishigaki  1   2 , Ryo Kinoshita  1 , Shoko Sakuraba  3 , Jun Sugihara  3 , Tadaki Suzuki  1 , Motoi Suzuki  1 , Daisuke Yoneoka  1
Affiliations

Comparison of Infection-Induced SARS-CoV-2 Seroprevalence Across Large-Scale Residual Samples From Blood Donors, Commercial Laboratories, and Health Checkups in Japan, 2023

Asuka Nishigaki et al. Open Forum Infect Dis. .

Abstract

We compared severe acute respiratory syndrome coronavirus 2 nucleocapsid antibody seroprevalence using 3 types of residual blood samples simultaneously collected in November-December 2023 from blood donors, commercial laboratories, and health checkups. Overall seroprevalence ranged from 53.5% to 58.8%, and notable variations were observed among the 30-39 and 50-59 age groups, highlighting the importance of multisource seroepidemiological surveillance.

Keywords: COVID-19; SARS-CoV-2; seroepidemiology; seroprevalence; surveillance.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. All authors: no reported conflicts.

Figures

Figure 1.
Figure 1.
Comparison of infection-induced severe acute respiratory syndrome coronavirus 2 seroprevalence among blood donors, commercial laboratories, and health checkups. The analysis was limited to 15 prefectures with specimens available for all 3 sample populations. Seroprevalence estimates were adjusted for age and sex distribution in the population of each prefecture.
See this image and copyright information in PMC

References

    1. Byambasuren O, Dobler CC, Bell K, et al. Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: systematic review. PLoS One 2021; 16:e0248946. - PMC - PubMed
    1. Erikstrup C, Laksafoss AD, Gladov J, et al. Seroprevalence and infection fatality rate of the SARS-CoV-2 omicron variant in Denmark: a nationwide serosurveillance study. Lancet Reg Health Eur 2022; 21:100479. - PMC - PubMed
    1. Keith RJ, Holm RH, Amraotkar AR, et al. Stratified simple random sampling versus volunteer community-wide sampling for estimates of COVID-19 prevalence. Am J Public Health 2023; 113:768–77. - PMC - PubMed
    1. Arashiro T, Arai S, Kinoshita R, et al. National seroepidemiological study of COVID-19 after the initial rollout of vaccines: before and at the peak of the Omicron-dominant period in Japan. Influenza Other Respir Viruses 2023; 17:e13094. - PMC - PubMed
    1. Brynildsrud O. COVID-19 prevalence estimation by random sampling in population—optimal sample pooling under varying assumptions about true prevalence. BMC Med Res Methodol 2020; 20:196. - PMC - PubMed